April 1, 2012

The SSO conference was a critically important event in the company's history to date

The Annual Cancer Symposium of the Society of Surgical Oncology in Orlando late last month was a critically important event in the history of the company. As more information comes out about what Moffitt has fully demonstrated, I think it will become clear how seminal Moffitt's work was and is.

Reproducibility. A topic I will blog about in an upcoming post, Moffitt reproduced the outcome of Craig's prior work that first pointed to PV-10 inducing systemic effects (anti-tumor immunologic processes stimulated by PV-10 chemoablation).

Accelerated approval for metastatic melanoma. The full scope of Moffitt's work (completed, in-process and in the near future) makes AA a real possibility. Recall Craig's quote in the company's January PR: "...and whether emerging results from ongoing immunologic mechanism of action studies can be used to support accelerated approval in the U.S."

A systemic treatment. Moffitt's work also buttresses PV-10 as a systemic treatment and, thus, the company's significant valuation hurdle figure.

Questions, questions, questions. More answers now create more questions.

  • Moffitt's poster at SSO dealt with metastatic melanoma. Did (Has) Moffitt do (done) work on other indications? If so, what were these other indications: HCC/liver, pancreas, breast, colorectal, etc.?
  • When will immunology-related human trials commence (the previously termed Phase 2b trial, I believe)? Q2? Later?

No comments:

Post a Comment